ATLASCartesian Therapeutics (RNAC) earnings date: Nov 5, 2026
Cartesian Therapeutics (RNAC) reports earnings for the quarter ended Sep 30, 2026 on Thu, Nov 5, 2026, before the open. Analysts expect EPS of -$1.02.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on RNAC
| Last price | $6.49 (-3.9%) |
|---|---|
| Normal 1-day range (±1σ) | ±3.5% |
| Earnings beat history | Beat the EPS estimate in 3 of the last 4 reports |
These figures come from the same calibrated model and valuation as the Cartesian Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Cartesian Therapeutics reports on Nov 5, 2026. One email the day before, with ATLAS’s read on Cartesian Therapeutics. You can switch it off at any time.
Alert me before RNAC reportsFree to start. Creating an account takes under a minute.
RNAC earnings at a glance
| Next report (confirmed) | Thu, Nov 5, 2026 |
|---|---|
| Time | Before the open |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$1.02 |
| Last report | Jul 30, 2026 · Beat |
| Beat rate (last 4 reports) | 3 of 4 (75%) |
| Average EPS surprise | +18.9% |
| Average move around a report | ±4.6% (last 4) |
| Sector | Healthcare · Biotechnology |
Cartesian Therapeutics earnings history: last 4 reports
Cartesian Therapeutics last reported on Jul 30, 2026: EPS of $0.29 against an estimate of $0.20 (+45.0% surprise), a beat.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Jul 30, 2026 | $0.20 | $0.29 | +45.0% | Beat | +5.1% |
| Jul 16, 2026 | $0.75 | $1.11 | +48.0% | Beat | -4.8% |
| May 8, 2026 | $0.11 | $0.13 | +18.2% | Beat | +4.5% |
| Apr 30, 2026 | -$0.70 | -$0.95 | -35.7% | Miss | -3.9% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for RNAC
See the fair value, the probability range and the earnings history of Cartesian Therapeutics on its ATLAS page.
Cartesian Therapeutics (RNAC) stock analysisPlans from €3.99 a month.
Cartesian Therapeutics earnings: frequently asked questions
When does Cartesian Therapeutics (RNAC) report earnings?
Cartesian Therapeutics is scheduled to report on Thursday, November 5, 2026, before the open. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for RNAC?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$1.02 per share (USD). Estimates can change before the report.
How often does RNAC beat earnings estimates?
Of its last 4 reports with a recorded result, Cartesian Therapeutics beat the EPS estimate 3 times; the average surprise was +18.9%. Past results do not predict the next one.
How much does RNAC move around earnings?
Over its last 4 reports the stock moved an average of 4.6% (absolute, from the close before the report day to the close after it), and finished higher 2 of 4 times.
Did Cartesian Therapeutics beat earnings estimates last quarter?
Cartesian Therapeutics last reported on Jul 30, 2026: EPS of $0.29 against an estimate of $0.20 (+45.0% surprise), a beat.
How much does RNAC usually move in a day?
On a normal trading day the ATLAS model puts RNAC’s one-day range at about ±3.5%, with a 49% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Thu, Nov 5, 2026
Educational information, not investment advice. Disclaimer